EMILY SWARTLEY: Open Payments
NPI 1417523192 · WATERLOO, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$867 in 91 payments from 13 companies in 2025. Trend: 2023 $1,495 · 2024 $807 · 2025 $867
Food & beverage: $867
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $232 |
| Neurocrine BioSciences, Inc. | 26 | $155 |
| E.R. Squibb & Sons, L.L.C. | 4 | $113 |
| Axsome Therapeutics, Inc. | 5 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| Alkermes, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Janssen Pharmaceuticals, Inc | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
Products named: VRAYLAR, INGREZZA, COBENFY, Auvelity, REXULTI, CAPLYTA, ARISTADA, INVEGA SUSTENNA.
Industry payments across IA — which companies pay providers there.
